ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly providing misleading statements regarding its growth potential and market capabilities during the period from May 7, 2025, to July 28, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Novo Nordisk made overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the GLP-1 market [5]. - Defendants are accused of overstating the likelihood of patients switching to Novo Nordisk's branded alternatives and the company's ability to penetrate the GLP-1 market [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering significant amounts for clients [4]. - Investors are advised to select qualified legal counsel with a proven history in leadership roles within class action lawsuits [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors can choose to remain absent or select their own counsel [7].